MaxCyte Inc

MXCT remains in a Stage 2 advance, evidenced by higher highs and higher lows over the past quarter, but the active Blow-Off Top pattern signals a terminal phase and elevated transition risk. Price is currently pulling back into the rising 9/21 EMA zone, offering a favorable execution point, with short-term indicators in neutral territory and no clear exhaustion. Medium-term structure remains bullish as long as intermediate support holds, although the long-term downtrend suggests caution. Overall, conditions align for tactical participation on the long side now.

• ↑$147.7 M cash and no debt provides strategic investment flexibility
• ↑SPL program-related revenue up 62% YoY to $3.4 M on clinical milestones
• ↓Q1 total revenue declined 7% YoY to $9.7 M, missing growth targets